Forte Biosciences (FBRX) Equity Average (2017 - 2020)
Historic Equity Average for Forte Biosciences (FBRX) over the last 4 years, with Q3 2020 value amounting to $22.6 million.
- Forte Biosciences' Equity Average fell 1970.12% to $22.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $22.6 million, marking a year-over-year decrease of 1970.12%. This contributed to the annual value of $26.7 million for FY2019, which is 5869.59% down from last year.
- Latest data reveals that Forte Biosciences reported Equity Average of $22.6 million as of Q3 2020, which was down 1970.12% from $13.5 million recorded in Q2 2020.
- In the past 5 years, Forte Biosciences' Equity Average ranged from a high of $84.3 million in Q3 2017 and a low of -$128.7 million during Q1 2017
- For the 4-year period, Forte Biosciences' Equity Average averaged around $26.0 million, with its median value being $40.7 million (2019).
- Its Equity Average has fluctuated over the past 5 years, first soared by 33846.1% in 2018, then crashed by 10260.88% in 2020.
- Forte Biosciences' Equity Average (Quarter) stood at $75.6 million in 2017, then plummeted by 30.02% to $52.9 million in 2018, then tumbled by 85.79% to $7.5 million in 2019, then soared by 200.69% to $22.6 million in 2020.
- Its last three reported values are $22.6 million in Q3 2020, $13.5 million for Q2 2020, and -$1.3 million during Q1 2020.